Amgen Inc. (AMGN) News Today: Latest Market and Industry Updates
468.03
2.80
0.60 %
At close
11/11
USD
Daily range
459.14
468.46
468.46
Weekly range
456.03
481.65
481.65
Amgen stock holds steady as late-breaking Phase 3 Sjogrens results
Amgen presented late-breaking Phase 3 results for its investigational Sjogrens disease therapy at ACR26, highlighting improvements in systemic disease activity and symptoms. Separately, the stock ...
Amgen reported Q3 2026 earnings: Will AMGN hold $448.91 support?
Amgen reported its third quarter 2026 earnings. The stock is down 1.2% on the day at $459.69.Amgen reported its Q3 2026 earnings. The company stated it delivered another strong quarter, reflecting ...
Amgen stock edges higher as Q3 2026 results report date announcement
Amgen will report its third quarter 2026 financial results on November 3, an announcement that will provide insight into performance at one of the world's largest biotech drugmakers, employing ...
Amgen presents late-breaking data for DLL3-targeting T-cell engager as stock falls 1.7%
Amgen presented new clinical data for its DLL3-targeting T-cell engager at ESMO26, with results also published in NEJM. The stock is down 1.7% on the day at $439.26.Amgen presented late-breaking ...
Amgen stock climbs while resistance at $447.12 approaches
Amgen Inc. (AMGN) stock is trading at $438.43, up 3.17% on the day. The stock sits above its short-, medium-, and long-term moving averages, reflecting bullish ...
Why is Amgen stock up 3.3% today?
Amgen Inc. (AMGN) surged 3.36% after increasing investor interest on late-stage clinical trial success and strong institutional activity drove fresh demand. The move is supported by persistent ...
Amgen stock breakout attempt: Upside targets to watch
Amgen Inc. (AMGN) stock is trading at $407.42, gaining 3.5% on the day. The price is positioned above its key moving averages, reflecting continued strength in recent ...
Amgen study met its primary endpoint after stock ends session up 2%
Amgen announced that a Phase 3 study of its investigational therapy for patients with moderate-to-severe Sjogren’s disease activity reached its primary endpoint on September 7, 2026. Separately, ...
AMGN slides as selloff dominates the short-term trend
Amgen (AMGN) stock is trading at $397.01, marking a decline of 9.19% on the day. The price sits below its key moving averages, indicating continued short-term selling ...
Amgen announces Phase 3 DLL3-therapy study met primary endpoint as stock falls 7.5%
Amgen announced on August 21, 2026, that a Phase 3 trial evaluating its DLL3-targeting therapy as part of first-line maintenance for extensive-stage small cell lung cancer met its primary ...
Amgen stock price prediction: Double-digit sales growth strengthens rally outlook
Amgen Inc. (AMGN) stock is trading at $442.51, posting a strong daily gain of 4.02%. The price is positioned above its key short- and long-term moving averages, ...
Amgen stock resistance test: Breakout levels to watch
Amgen Inc. (AMGN) stock is trading at $413.76, up 4.72% on the day. The price is holding well above its key moving averages and near the session high, with firm intraday ...
Amgen stock slides 1.64 percent to $378.89 as price tests crucial $378.22 support
Amgen is set to report its second-quarter 2026 financial results tomorrow, the company said. At the same time, Amgen stock is down 1.6% on the day at $378.89.Amgen, through its official account, ...
Amgen edges higher to $387.77 ahead of Q2 2026 results announcement, Amgen reports
Amgen will report its Q2 2026 financial results on Tuesday, according to Amgen.The company posted a link for further details. The stock trades under the ticker AMGN.[highlights-block]Bullish ...
Amgen stock rallies toward 52-week high after CHMP positive opinion for cardiovascular drug
Amgen said it received a positive opinion today from the EMA's Committee for Medicinal Products for Human Use as an important step towards expanding treatment options for adults at high ...
FDA receives additional data for Tavneos lifts Amgen stock toward $402.79 resistance
Amgen Inc. (AMGN) stock is trading at $392.5 after rising 4.36% today. The price is above its key short- and medium-term moving averages, confirming a strong position ...
Amgen stock gains 1.23% as Amgen features in new MrBeast video amid bullish momentum
Amgen appears in MrBeast's newest video, the company said in a tweet.The video showcases Amgen, MrBeast, Stand Up To Cancer, and partners working to bring attention to the need for pediatric ...
Amgen edges higher to $347.82 as it joins HHS roundtable on clinical trial access
Amgen expressed appreciation to the U.S. Department of Health and Human Services for organizing a Clinical Trials Roundtable.The company said clinical trials are key to bringing new medicines to ...
Amgen stock consolidates near $348 amid robust Research Triangle growth
Amgen is investing more than $1.5 billion in North Carolina's life sciences ecosystem, the company said on social media.Amgen says the investment contributes to innovation, growth, and opportunity ...
+3.35% for Amgen stock as Gilpin, ING Groep NV, Motley Fool increase holdings
Amgen Inc. (AMGN) stock is trading at $349.04, up 3.35% today. The price currently sits above its key moving averages, reflecting momentum in the current ...
Amgen stock extends rally above $349 with bullish momentum and overbought signals
Amgen shared new data on cardiometabolic care at the #ADASciSessions 2026, the company said in a tweet.Amgen said the data reinforce the need for more integrated approaches to prevention, risk ...
